Real-World Experience of Rapid Obinutuzumab Administration: Time to Change Obinutuzumab Infusion Rates

被引：0
|
作者：
Cunningham, Joel [1 ]
Sparksman, David [1 ]
Gordon-Walker, Dominic [1 ]
Sarkies, Patrick [1 ]
De Silva, Ravindu [1 ]
Small, Matthew [1 ]
Collins, Angela [1 ]
Shah, Nimish [1 ]
机构：
[1] Norfolk & Norwich Univ Hosp, Deparment Haematol, Norwich, Norfolk, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH22-PO59
引用
收藏
页码：107 / 107
页数：1
相关论文
共 50 条
  • [21] REAL-WORLD RECURRENCE RATES OF COLORECTAL CANCER OVER TIME
    Kunst, Natalia R.
    Alarid-Escudero, Fernando
    Aas, Eline
    Coupe, Veerle
    Kuntz, Karen M.
    MEDICAL DECISION MAKING, 2020, 40 (01) : E227 - E228
  • [22] Patients and physicians report a positive infusion experience with eptinezumab in the real-world setting
    Argoff, C.
    Khan, F.
    Herzog, S.
    Smith, R.
    Kotak, S.
    Sopina, L.
    Soni-Brahmbhatt, S.
    Kymes, S.
    HEADACHE, 2023, 63 : 149 - 150
  • [23] The Short-Term Efficacy and Safety of Obinutuzumab Plus Chemotherapy in B-NHL with High Tumor Burden: A Real-World, Retrospective Study
    Wan, Xin
    Guo, Wei
    Wang, Xingtong
    Zhao, Yangzhi
    Li, Jia
    Li, Junna
    Zhan, Zhumei
    Bai, Ou
    BLOOD, 2022, 140 : 11977 - 11978
  • [24] Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group
    Paszkiewicz-Kozik, Ewa
    Hus, Iwona
    Palka, Monika
    Debowska, Malgorzata
    Konska, Agnieszka
    Kotarska, Martyna
    Tyczynska, Agata
    Joks, Monika
    Twardosz, Maja
    Giza, Agnieszka
    Wasik-Szczepanek, Ewa
    Kalicinska, Elzbieta
    Wisniewska, Anna
    Morawska, Marta
    Lewicka, Barbara
    Szymanski, Marcin
    Targonski, Lukasz
    Romejko-Jarosinska, Joanna
    Drozd-Sokolowska, Joanna
    Subocz, Edyta
    Swoboda, Ryszard
    Dlugosz-Danecka, Monika
    Lech-Maranda, Ewa
    Walewski, Jan
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 32 (01): : 131 - 136
  • [25] Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study
    Berger, Tamar
    Shochat, Tzippy
    Aumann, Shlomzion
    Nachmias, Boaz
    Goldschmidt, Neta
    Horesh, Nurit
    Harel, Reut
    Aviv, Ariel
    Shmerts, Ella
    Abadi, Uri
    Shimony, Shai
    Raanani, Pia
    Gafter-Gvili, Anat
    Gurion, Ronit
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2127 - 2136
  • [26] Real-World Experience with Ofatumumab
    Thomas, K.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 202 - 203
  • [27] Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia
    Bourrier, Nicole
    Landego, Ivan
    Bucher, Oliver
    Squires, Mandy
    Streu, Erin
    Hibbert, Irena
    Whiteside, Theresa
    Gibson, Spencer B.
    Geirnaert, Marc
    Johnston, James B.
    Dawe, David E.
    Banerji, Versha
    BMC CANCER, 2022, 22 (01)
  • [28] Real-world experience - Reply
    Hutchinson, D
    CHEMICAL ENGINEERING PROGRESS, 1998, 94 (03) : 8 - 8
  • [29] Real-World Experience with Ocrelizumab
    Moss, Brandon P.
    Utigard, Erica
    Baldassari, Laura E.
    Cohen, Jeffrey A.
    Ontaneda, Daniel D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 69 - 70
  • [30] Real-world experience with ocrelizumab
    Moss, B.
    Parrotta, E.
    Baldassari, L.
    Planchon, S.
    Cohen, J.
    Ontaneda, D.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 780 - 781
12345